Mutant p53 targeting by the low molecular weight compound STIMA-1

Molecular Oncology

Volumn 2, Issue 1, 2008, Pages 70-80

  Zache, Nicole ^a   Lambert, Jeremy M R ^a,b   Rökaeus, Nina ^a   Shen, Jinfeng ^a   Hainaut, Pierre ^b   Bergman, Jan ^a   Wiman, Klas G ^a   Bykov, Vladimir J N ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Apoptosis; Cancer therapy; CP 31398; Mutant p53 reactivation; STIMA 1

Indexed keywords

2 VINYLQUINAZOLIN 4(3H) ONE; 4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; PROTEIN P53; QUINAZOLINE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; CULTURE MEDIUM; DIPLOIDY; FIBROBLAST; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN INDUCTION; TUMOR; TUMOR CELL;

EID: 43649096147     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2008.02.004     Document Type: Article

References (39)

1. M. Bhanoori C.R. Yellaturu S.K. Ghosh A. Hassid L.K. Jennings G.N. Rao Thiol alkylation inhibits the mitogenic effects of platelet-derived growth factor and renders it proapoptotic via activation of STATs and p53 and induction of expression of caspase1 and p21(waf1/cip1) Oncogene 22 2003 117 130
2. M.T. Bogert G.D. Beal Researches on quinazolones. XXVI. Synthesis of some stilbazoles, hydrazones and Schiff bases in the 4-quinazolone group J. Am. Chem. Soc. 32 1911 1654 1664
3. A.L. Borresen-Dale TP53 and breast cancer Hum. Mutat. 21 2003 292 300
4. V.J. Bykov N. Issaeva G. Selivanova K.G. Wiman Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database Carcinogenesis 23 2002 2011 2018
5. V.J. Bykov N. Issaeva A. Shilov M. Hultcrantz E. Pugacheva P. Chumakov J. Bergman K.G. Wiman G. Selivanova Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound Nat. Med. 8 2002 282 288
6. V.J. Bykov G. Selivanova K.G. Wiman Small molecules that reactivate mutant p53 Eur. J. Cancer 39 2003 1828 1834
7. V.J. Bykov N. Issaeva N. Zache A. Shilov M. Hultcrantz J. Bergman G. Selivanova K.G. Wiman Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs J. Biol. Chem. 280 2005 30384 30391
8. V.J. Bykov N. Zache H. Stridh J. Westman J. Bergman G. Selivanova K.G. Wiman PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis Oncogene 24 2005 3484 3491
9. B.G. Campling W.S. El-Deiry Clinical implications of p53 mutations in lung cancer Methods Mol. Med. 75 2003 53 77
10. R.T. Dorr D.D. Von Hoff Cancer Chemotherapy Handbook second ed. 1994 Appleton and Lange Norwalk, CT
11. W.S. El-Deiry Regulation of p53 downstream genes Semin. Cancer Biol. 8 1998 345 357
12. B.A. Foster H.A. Coffey M.J. Morin F. Rastinejad Pharmacological rescue of mutant p53 conformation and function Science 286 1999 2507 2510
13. A. Friedler L.O. Hansson D.B. Veprintsev S.M. Freund T.M. Rippin P.V. Nikolova M.R. Proctor S. Rudiger A.R. Fersht A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants Proc. Natl. Acad. Sci. U.S.A. 99 2002 937 942
14. M.S. Greenblatt W.P. Bennett M. Hollstein C.C. Harris Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis Cancer Res. 54 1994 4855 4878
15. P. Hainaut M. Hollstein p53 and human cancer: the first ten thousand mutations Adv. Cancer Res. 77 2000 81 137
16. P. Hainaut J. Milner Redox modulation of p53 conformation and sequence-specific DNA binding in vitro Cancer Res. 53 1993 4469 4473
17. J.B. Jiang D.P. Hesson B.A. Dusak D.L. Dexter G.J. Kang E. Hamel Synthesis and biological evaluation of 2-styrylquinazolin-4(3H)-ones, a new class of antimitotic anticancer agents which inhibit tubulin polymerization J. Med. Chem. 33 1990 1721 1728
18. L.R. Kelland N.P. Farrell Platinum-based Drugs in Cancer Therapy 2000 Humana Press Totowa, NJ
19. A.J. Levine p53, the cellular gatekeeper for growth and division Cell 88 1997 323 331
20. Y. Luu J. Bush K.J. Cheung Jr. G. Li The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/caspase-9 pathway Exp. Cell Res. 276 2002 214 222
21. D. Matas A. Sigal P. Stambolsky M. Milyavsky L. Weisz D. Schwartz N. Goldfinger V. Rotter Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis Embo J. 20 2001 4163 4172
22. S. North O. Pluquet D. Maurici F. El-Ghissassi P. Hainaut Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1 Mol. Carcinog. 33 2002 181 188
23. T. Ohnishi H. Matsumoto X. Wang A. Takahashi T. Tamamoto K. Ohnishi Restoration by glycerol of p53-dependent apoptosis in cells bearing the mutant p53 gene Int. J. Radiat. Biol. 75 1999 1095 1098
24. M. Olivier R. Eeles M. Hollstein M.A. Khan C.C. Harris P. Hainaut The IARC TP53 database: new online mutation analysis and recommendations to users Hum. Mutat. 19 2002 607 614
25. R. Rainwater D. Parks M.E. Anderson P. Tegtmeyer K. Mann Role of cysteine residues in regulation of p53 function Mol. Cell. Biol. 15 1995 3892 3903
26. T.M. Rippin V.J. Bykov S.M. Freund G. Selivanova K.G. Wiman A.R. Fersht Characterization of the p53-rescue drug CP-31398 in vitro and in living cells Oncogene 21 2002 2119 2129
27. K.M. Ryan A.C. Phillips K.H. Vousden Regulation and function of the p53 tumor suppressor protein Curr. Opin. Cell Biol. 13 2001 332 337
28. Y. Samuels-Lev D.J. O'Connor D. Bergamaschi G. Trigiante J.K. Hsieh S. Zhong I. Campargue L. Naumovski T. Crook X. Lu ASPP proteins specifically stimulate the apoptotic function of p53 Mol. Cell 8 2001 781 794
29. G. Selivanova V. Iotsova I. Okan M. Fritsche M. Strom B. Groner R.C. Grafstrom K.G. Wiman Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain Nat. Med. 3 1997 632 638
30. Y.R. Seo M.R. Kelley M.L. Smith Selenomethionine regulation of p53 by a ref1-dependent redox mechanism Proc. Natl. Acad. Sci. U.S.A. 99 2002 14548 14553
31. L.M. Shi Y. Fan T.G. Myers P.M. O'Connor K.D. Paull S.H. Friend J.N. Weinstein Mining the NCI anticancer drug discovery databases: genetic function approximation for the QSAR study of anticancer ellipticine analogues J. Chem. Inf. Comput. Sci. 38 1998 189 199
32. M.A. Smith J. March March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure 2001 John Wiley & Sons New York
33. X.Z. Sun C. Vinci L. Makmura S. Han D. Tran J. Nguyen M. Hamann S. Grazziani S. Sheppard M. Gutova F. Zhou J. Thomas J. Momand Formation of disulfide bond in p53 correlates with inhibition of DNA binding and tetramerization Antioxid. Redox Signal 5 2003 655 665
34. R. Takimoto W. Wang D.T. Dicker F. Rastinejad J. Lyssikatos W.S. El-Deiry The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein Cancer Biol. Ther. 1 2002 47 55
35. B. Vogelstein D. Lane A.J. Levine Surfing the p53 network Nature 408 2000 307 310
36. W. Wang R. Takimoto F. Rastinejad W.S. El-Deiry Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding Mol. Cell. Biol. 23 2003 2171 2181
37. J. Wischhusen U. Naumann H. Ohgaki F. Rastinejad M. Weller CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death Oncogene 22 2003 8233 8245
38. A. Witt J. Bergman Synthesis and reactions of some 2-Vinyl-3 H -quinazolin-4-ones Tetrahedron 56 2000 7245 7253
39. A. Witt J. Bergman Total syntheses of the benzodiazepine alkaloids circumdatin F and circumdatin C J. Org. Chem. 66 2001 2784 2788